全文获取类型
收费全文 | 1386196篇 |
免费 | 104654篇 |
国内免费 | 9765篇 |
专业分类
耳鼻咽喉 | 19172篇 |
儿科学 | 43642篇 |
妇产科学 | 40039篇 |
基础医学 | 199538篇 |
口腔科学 | 37309篇 |
临床医学 | 122788篇 |
内科学 | 267957篇 |
皮肤病学 | 27821篇 |
神经病学 | 104922篇 |
特种医学 | 54063篇 |
外国民族医学 | 436篇 |
外科学 | 209241篇 |
综合类 | 44958篇 |
现状与发展 | 25篇 |
一般理论 | 305篇 |
预防医学 | 99252篇 |
眼科学 | 32474篇 |
药学 | 109654篇 |
112篇 | |
中国医学 | 8419篇 |
肿瘤学 | 78488篇 |
出版年
2021年 | 11791篇 |
2019年 | 12015篇 |
2018年 | 15827篇 |
2017年 | 12525篇 |
2016年 | 13425篇 |
2015年 | 16714篇 |
2014年 | 22386篇 |
2013年 | 30288篇 |
2012年 | 42182篇 |
2011年 | 45456篇 |
2010年 | 27014篇 |
2009年 | 24621篇 |
2008年 | 41283篇 |
2007年 | 44207篇 |
2006年 | 44813篇 |
2005年 | 44093篇 |
2004年 | 40698篇 |
2003年 | 39383篇 |
2002年 | 38280篇 |
2001年 | 60837篇 |
2000年 | 62394篇 |
1999年 | 53532篇 |
1998年 | 15557篇 |
1997年 | 14076篇 |
1996年 | 13777篇 |
1995年 | 13700篇 |
1994年 | 12940篇 |
1992年 | 42034篇 |
1991年 | 41326篇 |
1990年 | 40690篇 |
1989年 | 39416篇 |
1988年 | 36709篇 |
1987年 | 35909篇 |
1986年 | 34141篇 |
1985年 | 32518篇 |
1984年 | 24113篇 |
1983年 | 20929篇 |
1982年 | 12415篇 |
1979年 | 22695篇 |
1978年 | 15885篇 |
1977年 | 13720篇 |
1976年 | 12980篇 |
1975年 | 14210篇 |
1974年 | 16710篇 |
1973年 | 16074篇 |
1972年 | 15325篇 |
1971年 | 14244篇 |
1970年 | 13213篇 |
1969年 | 12736篇 |
1968年 | 11977篇 |
排序方式: 共有10000条查询结果,搜索用时 203 毫秒
61.
Willy Baccaglini Felipe A. Glina Cristiano Linck Pazeto Luis G. Medina Fernando Korkes Wanderley M. Bernardo Rene Sotelo Sidney Glina Giancarlo Marra Marco Moschini Xavier Cathelineau Rafael Sanchez-Salas 《Clinical genitourinary cancer》2021,19(1):3-11.e1
This meta-analysis focuses on the accuracy of upgrading to clinically significant prostate cancer (PCa) by multiparametric magnetic resonance imaging-targeted biopsy (MRI-TB) versus systematic biopsy (SB). We searched the Medline, Embase, Cochrane Central Register of Controlled Trials, Web of Science, Scopus, and Literatura Latino Americana em Ciências da Saúde databases through January 2020 for comparative, retrospective/prospective, paired-cohort, and randomized clinical trials with paired comparisons. The population consisted of patients with low-risk PCa in active surveillance with at least 1 index lesion on imaging. We evaluated the quality of evidence by using the Quality Assessment of Diagnostic Accuracy Studies-2 score. Group comparisons considered the differences between the area under the curve summary receiver operating characteristic curve in a 2-tailed method. We also compared the positive predictive value of the best single method (MRI-TB or SB) and the referral study test (combined biopsy, a combination of MRI-TB and SB). The meta-analysis included 6 studies enrolling 741 patients. The pooled sensitivity for the 2 groups was 0.79 (95% confidence interval, 0.74-0.83; I2 = 75%) and 0.67 (95% confidence interval, 0.63-0.74; I2 = 55.4%), respectively. The area under the curve for the MRI-TB and SB groups were 0.99 and 0.92 (P < .001), respectively. The positive predictive value for the MRI-TB and combined biopsy groups were similar. The accumulated evidence suggests better results for MRI-TB compared with SB. Therefore, use of MRI-TB alone may be preferable in patients in active surveillance harboring low-risk PCa. 相似文献
62.
Bingqi Ma Huijuan Meng Ye Tian Yingying Wang Tianqiang Song Ti Zhang Qiang Wu Yunlong Cui Huikai Li Wei Zhang Qiang Li 《Oncology Letters》2021,21(1)
Herpesvirus entry mediator (HVEM) displays dual signals in T-cell activation according to the ligands and intracytoplasmic effectors it interacts with. High HVEM expression may play an immunosuppressive role in several malignancies. The present study investigated the clinical impact of HVEM on intrahepatic cholangiocarcinoma (ICC), including its prognostic value, and association with clinicopathological features and immune status. The clinical data of 102 consecutive patients with ICC who underwent surgical treatment from January 2012 to December 2017 were collected. The expression of HVEM and different types of tumor-infiltrating lymphocytes (TILs) were investigated in ICC tissue samples by immunohistochemical staining. HVEM expression was detected in the tumor tissues of 92 (90.2%) patients with ICC. Patients with high HVEM expression were more likely to have increased peripheral blood lymphocyte (PBL) concentrations (P=0.031), decreased CEA (P=0.036), low TNM stage (P=0.043) and high frequencies of small-duct histological type (P=0.021) and BAP1 retained expression (P=0.010). Survival analysis showed that high HVEM expression was a favorable independent predictor of overall postoperative survival (P=0.034, hazard ratio=0.486, 95% confidence interval=0.249–0.945). In addition, no significant association of HVEM expression with CD4+ (P=0.512), CD8+ (P=0.750) or CD45RO+ (P=0.078) TILs was identified in the ICC tissues. These results indicate that HVEM may serve as a favorable prognostic marker for ICC. Furthermore, co-stimulatory signals from HVEM may play a dominant role in the progression of ICCs, which can be explained by an increase in the number of PBLs rather than a change in the number of TILs. However, the function of the HVEM network in ICC progression is complex and requires further study. 相似文献
63.
64.
G.R. Iball D. Tolan G.R. Avery L.H. Cope T. Hoare H. Lambie A. Lowe R.J. de Noronha C.L. Roberts M.E. Wilkinson P. Woolfall 《Clinical radiology》2021,76(8):626.e13-626.e21
65.
There have been a number of investigations of the efficacy and safety of etanercept. This study was performed to obtain long-term drug survival data (ie, time to drug discontinuation) for etanercept, and the reasons for its discontinuation. The study population consisted of patients with psoriatic arthritis and psoriasis followed up by our clinic, registered in the Turkish Psoriasis Registry (PSR-TR) and treated with etanercept for at least 4 weeks between January 1, 2005, and January 31, 2020. The efficacy of etanercept was evaluated in terms of the Psoriasis Area and Severity Index (PASI) 75, PASI 90 and PASI 100 response rates at 12, 24, 36, and 48 weeks, and annually thereafter. The behaviors of the patients with respect to the use of etanercept, and the outcomes of those who continued to use it during the COVID-19 pandemic, were also investigated. 相似文献
66.
67.
B.R. Mussmann S.D. Mørup P.M. Skov S. Foley A.S. Brenøe F. Eldahl G.M. Jørgensen H. Precht 《Radiography》2021,27(1):1-7
IntroductionOrgan-based tube current modulation (OBTCM) is designed for anterior dose reduction in Computed Tomography (CT). The purpose was to assess dose reduction capability in chest CT using three organ dose modulation systems at different kVp settings. Furthermore, noise, diagnostic image quality and tumour detection was assessed.MethodsA Lungman phantom was scanned with and without OBTCM at 80–135/140 kVp using three CT scanners; Canon Aquillion Prime, GE Revolution CT and Siemens Somatom Flash. Thermo-luminescent dosimeters were attached to the phantom surface and all scans were repeated five times. Image noise was measured in three ROIs at the level of the carina. Three observers visually scored the images using a fivestep scale. A Wilcoxon Signed-Rank test was used for statistical analysis of differences.ResultsUsing the GE revolution CT scanner, dose reductions between 1.10 mSv (12%) and 1.56 mSv (24%) (p < 0.01) were found in the anterior segment and no differences posteriorly and laterally. Total dose reductions between 0.64 (8%) and 0.91 mSv (13%) were found across kVp levels (p < 0.00001). Maximum noise increase with OBTCM was 0.8 HU. With the Canon system, anterior dose reductions of 6–10% and total dose reduction of 0.74–0.76 mSv across kVp levels (p < 0.001) were found with a maximum noise increase of 1.1 HU. For the Siemens system, dose increased by 22–51% anteriorly; except at 100 kVp where no dose difference was found. Noise decreased by 1 to 1.5 HU.ConclusionOrgan based tube current modulation is capable of anterior and total dose reduction with minimal loss of image quality in vendors that do not increase posterior dose.Implications for practiceThis research highlights the importance of being familiar with dose reduction technologies. 相似文献
68.
本研究拟探讨染料木黄酮对前列腺癌细胞LNCaP和CWR22RV1的增殖、迁移和侵袭能力的影响。一、材料与方法1.材料:前列腺癌细胞株LNCaP和CWR22RV1(中国科学院上海生命科学研究院);Genistein(天津科瑞泰科技有限公司);RPMI 1640、胎牛血清(FBS)、胰蛋白酶(美国Gibco公司);E-钙黏蛋白(E-cadherin)、N-钙黏蛋白(N-cadherin)、波形蛋白(Vimentin,Abcam公司);聚氰基丙烯酸正丁酯(BCA)试剂盒、十二烷基硫酸钠-聚丙烯酰胺凝胶电泳(SDS-PAGE)上样缓冲液(×5)及蛋白质印迹法(Western blot)试剂盒(上海市碧云天生物公司);2.实验方法:采用噻唑蓝(MTT)实验、划痕实验和Transwell实验检测Genistein对细胞增殖、迁移及侵袭能力的影响。采用Western blot检测E-cadherin、N-cadherin、Vimentin、CD44和Oct-4的表达水平。 相似文献
69.